Compare Enveric Biosciences Inc (ENVB) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Materials Select Sector SPDR Fund — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Materials Select Sector SPDR Fund trades at $49.23 (market cap $7.86B). The key difference: Materials Select Sector SPDR Fund is far larger — about 1174.9× Enveric Biosciences Inc's market cap, and Materials Select Sector SPDR Fund is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Materials Select Sector SPDR Fund for 70 Days on average.
| ENVB | XLB | |
|---|---|---|
Market Cap | $6.69M | $7.86B |
Volume | 41,141 | 9,786,394 |
Sector | Health | — |
52-Week High | $10.80 | $53.67 |
52-Week Low | $1.27 | $42.23 |
Typical Hold Time | 14 Days | 70 Days |
Enterprise Value | -$1.60M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
XLB trades at $48.98, down 1.51% for the day, with a bearish technical signal from moving averages. The materials sector ETF faces headwinds amid September's broader market weakness outside of technology. Recent analysis indicates the portfolio is heavily concentrated in chemicals (49% of assets) with construction materials appearing moderately overvalued. The fund offers low-cost exposure to large-cap U.S. materials companies but faces cyclical pricing pressures.
The materials sector shows potential from infrastructure and manufacturing trends, though much of the cyclical recovery appears priced in. Key risks include sector concentration, economic sensitivity, and competition from China in critical minerals. Analyst sentiment remains cautious with limited near-term upside potential despite long-term infrastructure tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
